AUTL — Autolus Therapeutics Share News
0.000.00%
Last trade - 00:00- $428.49m
- $476.32m
- $75.39m
Brief: Autolus Therapeutics Announces Pivotal Phase 2 Felix Study Of Obe-Cel In Adult R/R B-All Selected For An Oral Presentation At Eha
Autolus Therapeutics PLC reports results for the quarter ended in March - Earnings Summary
Brief: Autolus Therapeutics Reports First Quarter 2023 Financial Results And Operational Progress
Autolus Therapeutics PLC expected to post a loss of 27 cents a share - Earnings Preview
Brief: Autolus Therapeutics Selects Cardinal Health As U.S. Commercial Distribution Partner
Brief: Autolus Therapeutics Announces Data From Auto1/22 Trial
Brief: Autolus Therapeutics Announces Resignation Of Chief Financial Officer
Brief: Autolus Therapeutics Says No Business With Silicon Valley Bank
Autolus Therapeutics PLC reports results for the quarter ended in December - Earnings Summary
Autolus Therapeutics PLC expected to post a loss of 27 cents a share - Earnings Preview
Autolus Therapeutics rises on agreement with Cabaletta Bio
Brief: Autolus Therapeutics Collaborates With Cabaletta Bio For Autoimmune Disease Cell Therapies
Focus: Private equity acquires a taste for drug development
Brief: Autolus Announces Partial Exercise Of Underwriters' Option To Purchase Additional Adss
Biotech enters new year with worst days behind - Mizuho
Biotech enters new year with worst days behind - Mizuho
U.S. STOCKS ON THE MOVE-Johnson Outdoors, agilon health, Phreesia
U.S. STOCKS ON THE MOVE-Arcellex, Ambrx Biopharma, Boeing
U.S. STOCKS ON THE MOVE-Gold miners, Boeing, Ambrx Biopharma